Skip to main content

GE Healthcare and Abbott Scuttle $8B Deal for Diagnostics Units

NEW YORK (GenomeWeb News) — General Electric and Abbott have decided to scuttle their plan for GE to buy two of Abbott’s diagnostics divisions for around $8.13 billion, the firms said yesterday.
The companies, whose boards had approved the deal, said they were unable to agree on final terms.  
Abbott did not specify which “terms and conditions” killed the deal but maintained that holding the two businesses, which it said generated around $2.7 billion in 2006, will not change its earnings outlook for 2007.
GE Healthcare in January said it planned to buy Abbott’s point-of-care and in vitro diagnostics businesses as part of an effort to firm up its foothold in the diagnostics market.
GE CEO Jeffrey Immelt said at the time that Abbott’s share of the “growing diagnostics field is aligned with our objective to deliver a comprehensive array of diagnostic products around the world.”
Abbott had planned to divest the diagnostics segments in order to streamline its molecular business.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.